Oncology · AKT InhibitorRegulatory Approvalregulatorymid-term

AstraZeneca's Capivasertib Receives AP Status from FDA

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/23/2026, 6:31:44 AM

Assessment confidence: 90% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's Approval Pending status for AstraZeneca's Capivasertib signifies a critical step towards market entry in the oncology sector. This development could reshape competitive dynamics among AKT inhibitors, necessitating proactive strategies from other market players. Regulatory context from FDA (FDA AP — TRUQAP (SUPPL)) supports the near-term read. Assessment grounded in 29 ranked evidence items (29 high-relevance).

Strategic Assessment

Portfolio teams should prepare for potential competitive dynamics as Capivasertib approaches approval, including market positioning strategies. The strongest clinical anchor is Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase o (ClinicalTrials.gov), entity match (capivasertib). In Oncology · AKT Inhibitor, 7 regulatory and 6 competitive items passed relevance filtering for AstraZeneca.

Competitive Pressure

The most relevant competitive pressure comes from FDA approves capivasertib with abiraterone for PTEN-deficient prostate cancer (Humanexa Signals) — entity match (astrazeneca). Secondary pressure from FDA ODAC Recommends Truqap for PTEN-Deficient Prostate Cancer. This AP status indicates that AstraZeneca is progressing towards potential market entry for Capivasertib, which may impact competitors in the AKT inhibitor space.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — TRUQAP (SUPPL) (FDA). Entity match (astrazeneca); Regulatory pathway relevance (nda). The AP status indicates that AstraZeneca is on track for potential approval, which could lead to a swift market launch and necessitate compliance readiness from competitors.

Key Risks

Elevated medium regulatory exposure for AstraZeneca could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (Status Epilepticus Population Study (STEPS)) could weigh on AstraZeneca through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

As Capivasertib approaches approval, it could capture significant market share, affecting revenue projections for existing AKT inhibitors and prompting competitors to adjust their strategies.
Upside for AstraZeneca may improve if Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase o (ClinicalTrials.gov) delivers favorable follow-through.
Upside for AstraZeneca may improve if Mechanisms of traditional Chinese medicine in enhancing the efficacy and reducing the toxicity of immune checkpoint inhibitors via regulation of the tumor microenvironment and gut microbiota. (PubMed) delivers favorable follow-through.
Upside for AstraZeneca may improve if Testing New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should prepare for potential competitive dynamics as Capivasertib approaches approval, including market positioning strategies.

What Would Change This Assessment

This becomes more urgent if Monitor for the final approval decision and any subsequent market launch plans from AstraZeneca.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — TRUQAP (SUPPL)
FDAhigh relevance
Entity match (astrazeneca); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TRUQAP (SUPPL)
FDAhigh relevance
Entity match (astrazeneca); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TRUQAP (SUPPL)
FDAhigh relevance
Entity match (astrazeneca); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — FARXIGA (SUPPL)
FDAhigh relevance
Entity match (astrazeneca); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — QTERN (SUPPL)
FDAhigh relevance
Entity match (astrazeneca); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ACETAMINOPHEN AND IBUPROFEN (SUPPL)
FDAhigh relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — POKONZA (SUPPL)
FDAhigh relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View source

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase o
ClinicalTrials.govhigh relevance
Entity match (capivasertib)
FDA document
View source
Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate in Cervical Cancer
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Immunological Impact of Post Cell Therapy Treatment With FLT3 Inhibitors
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Cognitive Function in Rett Syndrome During Trofinetide Treatment
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Status Epilepticus Population Study (STEPS)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
ASk Questions in GYnecologic Oncology (ASQ-GYO)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation
ClinicalTrials.govhigh relevance
Entity match (astrazeneca)
FDA document
View source
Testing New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source

FDA approves capivasertib with abiraterone for PTEN-deficient prostate cancer
Humanexa Signalshigh relevance
Entity match (astrazeneca)
FDA ODAC Recommends Truqap for PTEN-Deficient Prostate Cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (AstraZeneca)
[Ad hoc announcement pursuant to Art.
Rochehigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Datroway approved in US as first TROP2-directed ADC for 1L triple-negative breast cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (AstraZeneca)
FDA Grants Approval for Gallium Ga-68 Gozetotide (ANDA216410)
Humanexa Signalshigh relevance
Sponsor/company relevance (AstraZeneca)

UBE2C promotes pancreatic cancer progression through PI3K/Akt/mTOR signaling pathway.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Self-perceived learning outcomes of academic detailing discussing rational therapy with proton pump inhibitors among general practitioners in Norway.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Type 2 diabetes remission in gynaecologic oncology patients completing an acute preoperative weight loss protocol: a case series.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Mechanisms of traditional Chinese medicine in enhancing the efficacy and reducing the toxicity of immune checkpoint inhibitors via regulation of the tumor microenvironment and gut microbiota.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Systematic identification of bacterial neuraminidase inhibitors from Psoralea corylifolia using ultrafiltration-UPLC-Q-Orbitrap-MS and molecular dynamics.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Discovery of azaindole/indole-fused pyrimidine tetracyclic scaffolds as novel potent CDK7 inhibitors.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

AstraZeneca
Capivasertib
competitors in oncology

Commercial impact

medium

As Capivasertib approaches approval, it could capture significant market share, affecting revenue projections for existing AKT inhibitors and prompting competitors to adjust their strategies.

Regulatory impact

medium

The AP status indicates that AstraZeneca is on track for potential approval, which could lead to a swift market launch and necessitate compliance readiness from competitors.

What to watch

Monitor for the final approval decision and any subsequent market launch plans from AstraZeneca.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.